ioki expands into the US: first customer won, own US subsidiary established
ioki has established its own US company and is building a local team • Market entry is the first concrete step of the international growth strategy • First ioki customer in the US: on-demand service for Georgetown University in

ioki has set out to advance individual public transit in the car-centric US market, combining mobility simulation with digital public transport solutions. As in
Dr. Michael Barillère-Scholz, co-founder and CEO of ioki, says: "The idea for ioki was born during a visit to the US. We were founded and grew in
Public transit in
In the US, transit authorities and operators face the same questions as in
The Georgetown University project is expected to be followed shortly by further services running on the ioki Platform and by mobility concepts based on ioki Analytics.
The US public transit industry will have the opportunity to get to know ioki and its products for the first time at the APTA 2026 TRANSform & EXPO. The American Public Transportation Association's (APTA) flagship trade show takes place
About ioki
ioki is Europe's leading technology company for digital mobility and the market leader for on-demand transport in the DACH region. With more than 230 projects, we are among the pioneers in data-driven transport planning and operations simulation. With our holistic solutions, we digitalize public transport and drive the sustainable mobility transition forward – together with our partners from cities, municipalities, and public transport operators.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ioki-expands-into-the-us-first-customer-won-own-us-subsidiary-established-302896167.html
SOURCE ioki
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Real Estate Expert Angela Worth Outlines How to Plan a Home Sale When Downsizing in HelloNation
- Dance Studio Expert Jeanine Nielson Explains Competitive vs. Recreational Dance and Cheer in HelloNation
- AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share